Analyst Research Report Snapshot

Title:

ESPERION THERAPEUTICS - STATIN ALTERNATIVE

Price:

$10.00

Provider:

Edison Investment Research

Date:

14 Aug 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

ESPR.OQ

Available for Immediate Download
Summary:

Esperion’s recent NASDAQ IPO raised $75m net (5.75m shares at $14/s), providing the funds to advance its once-daily ETC-1002 through two Phase IIb studies in hypercholesterolemia. ETC-1002 has shown LDL-C reductions comparable to statins thus far in statin-intolerant (SI) patients, which if repeated in future trials represents a potential blockbuster market opportunity, although long-term safety must also be established.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.